| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8725297 | Clinical Gastroenterology and Hepatology | 2018 | 18 Pages |
Abstract
For cirrhotic patients awaiting LT, pre-LT HCV treatment with DAAs is cost effective/saving in patients with MELD scores of 21 or lower, whereas post-LT HCV treatment is cost effective/saving in patients with MELD scores of 22 or higher.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Sumeyye Samur, Brian Kues, Turgay Ayer, Mark S. Roberts, Fasiha Kanwal, Chin Hur, Drew Michael S. Donnell, Raymond T. Chung, Jagpreet Chhatwal,